JY
RLMD icon

Jeff Yass’s Relmada Therapeutics RLMD Stock Holding History

Jeff Yass’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,800
Closed -$326K – 14346
2026
Q1 		$326K Buy
+46,800
New +$221K ﹤0.01% 10692
2024
Q4 		– Sell
-12,200
Closed -$39.5K – 13052
2024
Q3 		$39.5K Buy
+12,200
New +$39.5K ﹤0.01% 11461
2024
Q1 		– Sell
-25,600
Closed -$106K – 13164
2023
Q4 		$106K Buy
25,600
+2,300
+10% +$6.81K ﹤0.01% 11283
2023
Q3 		$69.9K Sell
23,300
-26,800
-53% -$79.6K ﹤0.01% 11136
2023
Q2 		$123K Buy
50,100
+19,000
+61% +$52.5K ﹤0.01% 10763
2023
Q1 		$70.3K Buy
31,100
+10,800
+53% +$37.2K ﹤0.01% 11529
2022
Q4 		$70.8K Sell
20,300
-602,200
-97% -$5.29M ﹤0.01% 11208
2022
Q3 		$23M Buy
622,500
+380,300
+157% +$10.5M 0.01% 1310
2022
Q2 		$4.6M Buy
242,200
+207,400
+596% +$4.52M ﹤0.01% 3318
2022
Q1 		$939K Buy
34,800
+25,900
+291% +$536K ﹤0.01% 7289
2021
Q4 		$201K Buy
+8,900
New +$198K ﹤0.01% 11439
2021
Q3 		– Sell
-80,200
Closed -$2.57M – 13427
2021
Q2 		$2.57M Buy
80,200
+62,800
+361% +$2.18M ﹤0.01% 5365
2021
Q1 		$613K Buy
+17,400
New +$609K ﹤0.01% 9007
2020
Q3 		– Sell
-11,400
Closed -$510K – 11059
2020
Q2 		$510K Buy
+11,400
New +$482K ﹤0.01% 7318

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's RLMD Position: Q2 2026 in Review

Jeff Yass reduced its Relmada Therapeutics (RLMD) stake by 97% in Q2 2026, selling an estimated $6.86M and leaving 30,108 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #11861.

Jeff Yass first reported a position in RLMD in Q4 2019 and has held it in 21 quarters since. The position peaked at $7.04M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Jeff Yass held 30,108 shares of Relmada Therapeutics worth $208K as of Q2 2026.
  • Jeff Yass sold 981,464 Relmada Therapeutics shares in Q2 2026, an estimated $6.86M.
  • Relmada Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11861 holding.
  • Jeff Yass first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Relmada Therapeutics position peaked at $7.04M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.